Brief reportExudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin
Section snippets
Case 1
A man aged 58 years had sudden visual loss in his right eye (OD). The left eye (OS) was functionally and clinically unremarkable. The patient’s OD best-corrected visual acuity was 10/50 according to the Early Treatment Diabetic Retinopathy Study (ETDRS) charts, and Pelli-Robson contrast sensitivity was 1.35. Fundus examination showed a large retinal macular detachment with hemorrhages. Fluorescein angiography disclosed an early hyperfluorescent, a late-leaking nodular zone in the foveal region,
Case 2
Patient 2 was a woman aged 57 years who was evaluated for sudden visual loss in her right eye. The left eye had poor visual function (best-corrected visual acuity 10/100, Pelli-Robson contrast sensitivity 0.60) due to a large macular zone of retinal pigment epithelium atrophic disturbances. The right eye ETDRS charts best-corrected visual acuity was 10/50 and the Pelli Robson contrast sensitivity was 1.20. At fundus examination, several hard exudates surrounding a large retinal macular
References (5)
- et al.
Idiopathic polypoidal choroidal vasculopathy of the macula
Ophthalmology
(1998) - et al.
Idiopathic polypoidal choroidal vasculopathy (IPCV)
Retina
(1990)
Cited by (92)
One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients
2012, American Journal of OphthalmologyCitation Excerpt :The mean number of reinjections was 1.2 in the current study, which was lower than the mean 5.6 reinjections in the PrONTO study.25 Previous studies have reported that PDT might be more effective for PCV compared with AMD, and the number of additional applications of PDT during the first year after the first treatment was lower than the number of retreatments for AMD.1–12,31,32 Although the results from those studies cannot be simply compared, PCV generally might respond well to both PDT and ranibizumab.
Evolving treatment paradigms for PCV
2022, Eye (Basingstoke)The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: a systematic review and meta-analysis
2021, Graefe's Archive for Clinical and Experimental Ophthalmology